Recent advances in liposomal drug-delivery systems (original) (raw)
Related papers
LIPOSOMAL DRUG DELIVERY SYSTEM: AN OVERVIEW
Shodhasamhita : Journal of Fundamental & Comparative Research, 2022
Liposomes were the first nanoscale drug to be approved for clinical use in 1995.A major advancement in liposome-based delivery methods has been made since that time, and these advancements have important therapeutic consequences. For example, this comprises liposomes that can remain in the body for a lengthy period of time, liposomes that can be nebulized and elastic liposomes that can be used for topical, oral, and transdermal distribution. In contrast to liposomes, existing guidance on novel delivery strategies has not been well-documented. Liposomal delivery systems are described in detail, along with the regulatory landscape surrounding commercialization efforts for higher-level complexity systems, expected requirements, and obstacles faced by companies looking to bring novel liposome-based systems to market for clinical use, in this in-depth assessment.
Liposomal Drug Delivery Systems: An Update Review
Current Drug Delivery, 2007
The discovery of liposome or lipid vesicle emerged from self forming enclosed lipid bi-layer upon hydration; liposome drug delivery systems have played a significant role in formulation of potent drug to improve therapeutics. Recently the liposome formulations are targeted to reduce toxicity and increase accumulation at the target site. There are several new methods of liposome preparation based on lipid drug interaction and liposome disposition mechanism including the inhibition of rapid clearance of liposome by controlling particle size, charge and surface hydration. Most clinical applications of liposomal drug delivery are targeting to tissue with or without expression of target recognition molecules on lipid membrane. The liposomes are characterized with respect to physical, chemical and biological parameters. The sizing of liposome is also critical parameter which helps characterize the liposome which is usually performed by sequential extrusion at relatively low pressure through polycarbonate membrane (PCM). This mode of drug delivery lends more safety and efficacy to administration of several classes of drugs like antiviral, antifungal, antimicrobial, vaccines, anti-tubercular drugs and gene therapeutics. Present applications of the liposomes are in the immunology, dermatology, vaccine adjuvant, eye disorders, brain targeting, infective disease and in tumour therapy. The new developments in this field are the specific binding properties of a drug-carrying liposome to a target cell such as a tumor cell and specific molecules in the body (antibodies, proteins, peptides etc.); stealth liposomes which are especially being used as carriers for hydrophilic (water soluble) anticancer drugs like doxorubicin, mitoxantrone; and bisphosphonate-liposome mediated depletion of macrophages. This review would be a help to the researchers working in the area of liposomal drug delivery.
Cancer Treatment Reviews, 1996
Recently, liposomal drug delivery systems have come of age, with three antifungal and two anticancer preparations having received final approval for clinical use in a number of countries around the world. A number of other liposomal formulations of drugs, including anticancer, antibacterial and anti-inflammatory drugs, are in early-to-late clinical trials. Ligand-and antibody-targeted applications, designed to further increase site-specific delivery of liposomal drugs, are currently being explored in a number of laboratories.
Liposomal drug delivery systems: From concept to clinical applications ☆
The first closed bilayer phospholipid systems, called liposomes, were described in 1965 and soon were proposed as drug delivery systems. The pioneering work of countless liposome researchers over almost 5 decades led to the development of important technical advances such as remote drug loading, extrusion for homogeneous size, long-circulating (PEGylated) liposomes, triggered release liposomes, liposomes containing nucleic acid polymers, ligand-targeted liposomes and liposomes containing combinations of drugs. These advances have led to numerous clinical trials in such diverse areas as the delivery of anti-cancer, anti-fungal and antibiotic drugs, the delivery of gene medicines, and the delivery of anesthetics and anti-inflammatory drugs. A number of liposomes (lipidic nanoparticles) are on the market, and many more are in the pipeline. Lipidic nanoparticles are the first nanomedicine delivery system to make the transition from concept to clinical application, and they are now an established technology platform with considerable clinical acceptance. We can look forward to many more clinical products in the future.
International Journal of Applied Pharmaceutics, 2017
Liposomes are an efficient novel drug delivery system. They are used because of their structure which is stable and due to their ability to accommodate both lipophilic and hydrophilic drug. Various fascinating types of liposomes have been developed in recent past to further enhance their utility. Long-circulating liposomes or stealth liposomes are able to hide from the defence system of the body and circulate for a longer time in the blood. Targeted liposomes namely immuno-liposomes consists of antibodies conjugated on their surface to improve the specificity of the cell. Liposomes have been modified as per the conditions of pH and temperature, specifically designed to improve drug delivery to targeted tumor cells. Liposomes are being used in the treatment of various diseases and there are various liposomal drug formulations available today. Liposomes can be used as carriers for genetic materials such as antisense, DNA, RNA which are useful in the treatment of diseases. Liposomes are also efficient carriers of cytokines which further activate macrophages. This review provides the detailed insight of types and applications of liposomes and the potential challenges in the development of liposomal drug delivery systems.
Progress with liposomal drug delivery systems: Formulation to therapy
2014
The closed bilayer phospholipid systems likely called liposomes, were first described in 1965 by Alec Bangham and soon were accepted as drug delivery systems. Work on liposomes by number of researchers led the technical advances. These advances have led to numerous clinical trials and studies in such diverse areas as the delivery of anti-cancer, anti-fungal and anti-biotic drugs, the delivery of gene medicines and drug delivery to site of action, long circulating PEGylated liposomes, triggered release liposomes and liposomes containing combinations of drugs. This review is a focus on recent advances and some of the relevant challenges faced in developing clinically relevant liposomal drug carriers. The main objective of pharmaceutical science is to design and develop dosage forms with fulfilling the therapeutic need of the patients effectively. The writing highlights all aspects of liposomes starting from compositions to therapeutic applications and strategies through preparation an...
Liposomal Drug Delivery Systems – A Review
Liposomes are spherical shaped lipoidal vesicles which are under extensive investigation as drug carriers for improving the bioavailability and delivery of therapeutic agents. Due to innovative developments in liposome technology, numerous liposome based drug delivery systems are currently in clinical trial, and recently some of them have been approved for clinical use. Formulation of drugs in liposomes has provided an opportunity to enhance the therapeutic indices of various agents mainly through alteration in their bio distribution. This review discusses the classification, formulation, characterization and potential applications of liposomes in drug delivery
Advancement and Patents on Liposomal Drug Delivery
2015
Liposomes derived from Greek: 'Lipos' means fat and 'Soma' means body. Liposomes increase efficacy and therapeutic index of drug, stability via encapsulation. They are biocompatible and completely biodegradable in nature. On structure parameters, liposomes are classified into large unilamellar, medium lamellar, giant unilamellar, oligolamellar etc. On preparation parameters, liposomes are classified into Single or oligolamellar vesicle made by reverse phase evaporation method, Multilamellar vesicle made by reverse phase evaporation method, Stable plurilamellar vesicle. On Composition and application, liposomes are classified into conventional liposome, fusogenic liposome, cationic liposome, long circulatory liposome etc. Liposomes are prepared bypassive loading technique and active loading techniques. Various marketed formulations are available in market of liposomes for different diseases.
Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical nanotechnology, 2015
Since the discovery of liposomes, the drug delivery technology has made a tremendous advancement in the field of medicine. Owing to their biocompatibility, efficacy, targeting ability and improved in vivo performance, liposomes has become popular as versatile drug carrier systems. Controlled and sustained drug release, lowered systemic toxicity and improved pharmacokinetic and pharmacodynamic properties of drug are the potential applications of liposomal drug delivery. Drugs encapsulated in liposomes can be targeted actively and passively to the tumor specific site with improved efficacy and reduced off-target effects. Development of multifunctional liposomes for targeting cell organelles, long acting (PEGylated) and with combination of drugs is a hot-topic of current research. In recent years, the focus of liposomal technology has been on the combined applications of diagnostics and therapeutics. The present work reviews the liposomal drug delivery field, summarizes the success of liposomal technology in translation from concept to clinical acceptance and recent developments in the delivery of anti-fungal, antibiotic, anti-inflammatory and anti-cancer drugs.